Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study.
Frahm N, Fneish F, Ellenberger D, Haas J, Loebermann M, Parciak T, Peters M, Pöhlau D, Rodgers J, Röper AL, Schilling S, Stahmann A, Temmes H, Zettl UK, Middleton RM. Frahm N, et al. Among authors: roper al. Lancet Reg Health Eur. 2022 Sep 2;22:100502. doi: 10.1016/j.lanepe.2022.100502. eCollection 2022 Nov. Lancet Reg Health Eur. 2022. PMID: 36090519 Free PMC article.
How is and how should healthcare for people with multiple sclerosis in Germany be designed?-The rationale and protocol for the mixed-methods study Multiple Sclerosis-Patient-Oriented Care in Lower Saxony (MS-PoV).
Krüger K, Fricke LM, Dilger EM, Thiele A, Schaubert K, Hoekstra D, Heidenreich F, Brütt AL, Stahmeyer JT, Stahmann A, Röper AL, Kubiak KP, Hemmerling M, Grau A, Eichstädt K, Behrens S, Krauth C. Krüger K, et al. Among authors: roper al. PLoS One. 2021 Nov 11;16(11):e0259855. doi: 10.1371/journal.pone.0259855. eCollection 2021. PLoS One. 2021. PMID: 34762697 Free PMC article.
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study.
Fneish F, Frahm N, Peters M, Ellenberger D, Haas J, Löbermann M, Pöhlau D, Röper AL, Schilling S, Stahmann A, Temmes H, Paul F, Zettl UK. Fneish F, et al. Among authors: roper al. Vaccines (Basel). 2023 Dec 16;11(12):1859. doi: 10.3390/vaccines11121859. Vaccines (Basel). 2023. PMID: 38140262 Free PMC article.
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study.
Frahm N, Fneish F, Ellenberger D, Haas J, Löbermann M, Peters M, Pöhlau D, Röper AL, Schilling S, Stahmann A, Temmes H, Paul F, Zettl UK. Frahm N, et al. Among authors: roper al. J Clin Med. 2023 May 24;12(11):3640. doi: 10.3390/jcm12113640. J Clin Med. 2023. PMID: 37297838 Free PMC article.